TG Therapeutics presented updated data from its ENHANCE Phase 3b trial at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. The data demonstrated a consistent safety and tolerability profile for 30-minute maintenance BRIUMVI infusions in over 80 patients, with all observed infusion-related reactions being mild (Grade 1) and fully resolving.
An independent presentation at the forum showcased real-world data from a single-center retrospective chart review involving over 160 individuals treated with BRIUMVI. This review indicated a safety and tolerability profile consistent with the ULTIMATE I & II Phase 3 trials.
The real-world data also highlighted improvements for patients who had experienced suboptimal outcomes on prior anti-CD20 therapies and subsequently switched to BRIUMVI. These findings reinforce the drug's potential benefits and its competitive standing in the multiple sclerosis treatment landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.